Nkgen BiotechNKGN
13F holders, Q3 2024 (September 30)19holders +2
3new positions
1sold out
1famous investor
$0.33avg. 13F price*
At the end of Q3 2024, 19 institutions reported holding Nkgen Biotech Inc. (NKGN) in their 13F filings, up 2 from Q2 2024. 3 opened new positions and 1 sold out. The largest holders were Meteora Capital, LLC ($334K), Polar Asset Management Partners Inc. ($258K) and University of Chicago ($208K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Nkgen Biotech Inc.
- CUSIP
- 65488A101
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $45K |
| Exits | 1 | $24K |
All 13F filers, Q2 2024 → Q3 2024: 684,297 shares bought and 332,404 shares sold, net +351,893 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 19 holders
| Meteora Capital, LLC | 0.09% | Reduce -24.3% | 884,745 | $334K |
| Polar Asset Management Partners Inc. | 0.01% | Add +9.4% | 1,181,872 | $258K |
| University of Chicago | 0.18% | No change | 550,000 | $208K |
| Diametric Capital, LP | 0.10% | Add +55.4% | 518,134 | $196K |
| Vanguard Group Inc. | 0.00% | Add +323.4% | 227,804 | $86K |
| Geode Capital Management, LLC | 0.00% | Add +64.7% | 112,714 | $43K |
| Citadel Advisors | 0.00% | New | 95,438 | $36K |
| Sequoia Financial Advisors, LLC | 0.00% | Add +273.0% | 69,000 | $26K |
| Northern Trust Corp. | 0.00% | No change | 29,082 | $11K |
| Two Sigma Securities, LLC | 0.00% | New | 24,475 | $9K |
| UBS Group AG | 0.00% | Reduce -66.6% | 14,646 | $6K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +306.8% | 11,735 | $4K |
| State Street Corp. | 0.00% | No change | 11,200 | $4K |
| Towneley Capital Management, Inc / DE | 0.00% | No change | 10,000 | $4K |
| HRT Financial LP | 0.00% | Reduce -9.4% | 10,318 | $3K |
| BlackRock, Inc. | 0.00% | — | 1,854 | $701 |
| Federation des caisses Desjardins du Quebec | 0.00% | No change | 500 | $189 |
| Bank of America Corp. | 0.00% | Add +112.0% | 106 | $40 |
| JPMorgan Chase & Co. | 0.00% | New | 31 | $12 |
"% of holder's portfolio" is NKGN's weight in each manager's 13F, not the share of Nkgen Biotech Inc. the manager owns.